Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma.
Saved in:
| Title: | Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma. |
|---|---|
| Authors: | Tap WD; Memorial Sloan Kettering Cancer Center, New York, New York., Cote GM; Mass General Cancer Center, Boston, Massachusetts., Burris H; Sarah Cannon Research Institute, Nashville, Tennessee., Gore L; University of Colorado School of Medicine and University of Colorado Cancer Center, Aurora, Colorado., Elias A; University of Colorado School of Medicine and University of Colorado Cancer Center, Aurora, Colorado., Beeram M; START Center for Cancer Care, San Antonio, Texas., Conley AP; MD Anderson Cancer Center, Houston, Texas., Gianolio DA; Servier Bio-Innovation, Boston, Massachusetts., Qu Z; Servier Bio-Innovation, Boston, Massachusetts., Pandya S; Servier Bio-Innovation, Boston, Massachusetts., Trent JC; Sylvester Comprehensive Cancer Center, Miami, Florida. |
| Source: | Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2025 Jun 03; Vol. 31 (11), pp. 2108-2114. |
| Publication Type: | Clinical Trial, Phase I; Journal Article; Multicenter Study |
| Journal Info: | Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
